Pathology: mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1);
mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | |||
NCI-2018-01106, 2022 | HIMALAYA, 2022 | CheckMate 9DW, 2024 | ||
nivolumab plus ipilimumab plus SoC | 1 | T1 | ||
nivolumab plus ipilimumab | 1 | T1 | ||
durvalumab plus tremelimumab | 1 | T1 | ||
VEGF(R) inhibitor | 0 | T0 | ||
nivolumab alone | 0 | T0 | ||
sorafenib | 0 | T0 |